Company Overview
Hims & Hers Health, Inc. functions as a consumer-first health and wellness platform designed to connect individuals directly with licensed healthcare professionals across the United States, United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and international markets. Operating within the Healthcare sector specifically as a Drug Manufacturers - Specialty & Generic entity, the company leverages its distribution model to offer a curated range of health and wellness products to a global audience. The organization employs a workforce of 2,442 people and maintains a total market capitalization of $5.51B. With annual revenue reaching $2.35B, these valuation figures indicate that the market assigns a significant premium to the company's business model, reflecting strong investor confidence in its ability to scale its proprietary telehealth and direct-to-consumer approach within the specialized pharmaceutical industry.
Financial Health
The company reported total revenue of $2.35B over the trailing twelve months, generating a net income of $128.37M and an EBITDA of $175.66M. The substantial gap between the $2.35B revenue and the $128.37M net income reveals a cost structure where operating expenses and taxes consume approximately 94.5% of top-line growth, leaving a profit margin of 5.5%. Despite high costs, the business generated positive free cash flow of $110.51M, which provides the organization with essential financial flexibility to fund operations, invest in technology, or acquire competitors without immediate reliance on external financing. Profitability is supported by a robust gross margin of 73.8%, indicating strong pricing power and low cost of goods sold relative to sales, while the operating margin sits at 2.7% and the profit margin at 5.5%, highlighting the impact of significant overhead costs on the bottom line. The balance sheet holds $577.49M in cash against $1.12B in total debt, resulting in a debt-to-equity ratio of 207.16, which characterizes a leveraged balance sheet rather than a conservative one. However, the current ratio stands at 1.90, suggesting that the company maintains adequate short-term liquidity to meet its obligations as they come due. Management effectiveness is further evidenced by a Return on Equity of 25.2% and a Return on Assets of 5.3%, demonstrating that the firm generates substantial returns on shareholder capital and utilizes its asset base efficiently to produce earnings.
Valuation Assessment
Valuation metrics show a trailing P/E ratio of 47.37 compared to a forward P/E of 16.11, implying that the market currently prices in a significant expected improvement in earnings trajectory over the coming year. The price-to-book ratio is 10.15, indicating that the stock trades at a substantial premium over its tangible book value, which often reflects intangible assets like brand equity and proprietary technology that are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 2.35 and an EV/EBITDA of 34.44 suggest that investors are willing to pay a high multiple for each dollar of sales and earnings, consistent with high-growth healthcare sectors. The stock has a 52-week high of $70.43 and a 52-week low of $13.74, and the current trading price sits significantly below the 52-week high, reflecting recent market volatility or a correction from previous peaks. The beta of 2.61 indicates that the stock exhibits high price volatility relative to the broader market, moving more than twice as much as the general index during periods of market fluctuation.
Growth & Income
Revenue growth accelerated to 28.4% year-over-year, while earnings growth contracted to -17.4% year-over-year, revealing that earnings are growing slower than revenue and implying that top-line expansion has not yet been fully translated into proportional profit growth due to scaling costs. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all of its net income back into the business to fuel expansion rather than distributing cash to shareholders. The divergence between strong revenue expansion and negative earnings growth, combined with a lack of dividend payments, defines a growth-oriented income profile where capital allocation is prioritized for organic development and market share acquisition. Overall, the financial profile presents a high-volatility, high-revenue-growth company that currently operates with a leveraged balance sheet and focuses entirely on reinvestment strategies to drive future profitability.